Sona Nanotech Inc (SONA) Price & Analysis

Compare

54 Followers

SONA Stock Chart & Stats

C$0.40

>-C$0.01(-2.00%)

At close: Jan 08 4:00 PM EST

C$0.40

>-C$0.01(-2.00%)

Day’s Range― - ―

52-Week RangeC$0.25 - C$0.91

Previous CloseN/A

Volume36.80K

Average Volume (3M)124.26K

Market Cap

C$41.18M

Enterprise ValueC$42.00M

Total Cash (Recent Filing)C$125.95K

Total Debt (Recent Filing)C$307.74K

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding113,005,360

10 Day Avg. Volume87,178

30 Day Avg. Volume124,263

Financial Highlights & Ratios

PEG Ratio-2.88

Price to Book (P/B)-1.80K

Price to Sales (P/S)0.00

P/FCF Ratio-35.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.06

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Gold Nanorod TechnologyThe company’s proprietary gold nanorod platform targets diagnostics and assay formats, providing a durable technology moat. A versatile materials platform can support multiple product applications and licensing, enabling long-term revenue pathways if commercialization execution succeeds.

Modest Absolute Debt With Downward TrendRelatively small reported debt and a multi-year downward trend reduce fixed financial obligations and interest exposure, preserving flexibility. This structural decline in leverage helps limit financing drag and supports survivability while commercial progress is pursued.

Cash Flow Tracks Reported LossesFCF aligning with net loss indicates losses aren’t being obscured by non‑cash adjustments or aggressive accounting. This transparency aids forecasting and governance, making cash needs and burn patterns more predictable for long‑term planning and funding decisions.

Bears Say

No Reported Revenue (2020–2025)Zero reported revenue over multiple years shows lack of commercialization traction or persistent product-market fit issues. This structural absence of sales undermines the core business model and implies ongoing dependence on financing rather than operating cash generation.

Persistent And Accelerating Cash BurnConsistent negative operating cash flow and worsening free cash flow indicate accelerating cash consumption and shrinking runway. Over months, this raises dilution and refinancing risk and constrains ability to invest in commercialization or R&D without external capital.

Negative Equity And Shrinking Asset BaseNegative equity and a sharp asset decline signal balance‑sheet deterioration, increasing financial fragility. This reduces borrowing capacity, may limit strategic options, and heightens insolvency risk during extended commercialization timelines absent material financing.

Sona Nanotech Inc News

Sona Nanotech’s Innovative Approach to Metastatic Melanoma: A Study Update

Sona Nanotech, Inc (($TSE:SONA)) announced an update on their ongoing clinical study. Study Overview: Sona Nanotech Inc, in...

5M ago

SONA

Sona Nanotech’s Innovative Approach to Metastatic Melanoma: A Clinical Study Update

Sona Nanotech, Inc (($TSE:SONA)) announced an update on their ongoing clinical study. Sona Nanotech, Inc. is spearheading a...

5M ago

SONA

Sona Nanotech to Host Webinar on Innovative Cancer Therapy Clinical Study

Sona Nanotech Inc ( ($TSE:SONA) ) has shared an announcement. Sona Nanotech Inc. has announced an upcoming investor...

5M ago

Sona Nanotech Advances Clinical Trial for Innovative Cancer Therapy

Sona Nanotech Inc ( ($TSE:SONA) ) has shared an announcement. Sona Nanotech Inc. has provided an update on...

7M ago

Sona Nanotech Receives Ethics Approval for Melanoma Therapy Pilot Study

The latest update is out from Sona Nanotech Inc ( ($TSE:SONA) ). Sona Nanotech Inc. has received ethics...

8M ago

Sona Nanotech Initiates Feasibility Study for Innovative Cancer Therapy

Sona Nanotech Inc ( ($TSE:SONA) ) has issued an update. Sona Nanotech Inc. has commenced dosing in an...

8M ago

Sona Nanotech Receives Approval for Melanoma Clinical Trial

Sona Nanotech Inc ( ($TSE:SONA) ) has shared an announcement. Sona Nanotech Inc. has received ethics committee approval...

9M ago

Sona Nanotech Initiates Clinical Trial for Innovative Cancer Therapy

Sona Nanotech Inc ( ($TSE:SONA) ) has issued an announcement. Sona Nanotech Inc. has announced a clinical trial...

9M ago

Sona Nanotech Achieves Key Milestone with Successful FDA Toxicity Study

Sona Nanotech Inc ( ($TSE:SONA) ) has shared an update. Sona Nanotech Inc. announced successful completion of an...

10M ago

Sona Nanotech Advances Towards Clinical Trials with Successful Endotoxin Testing

Sona Nanotech Inc ( ($TSE:SONA) ) has provided an update. Sona Nanotech Inc. announced the successful completion of...

10M ago

SONA FAQ

What was Sona Nanotech Inc’s price range in the past 12 months?

Sona Nanotech Inc lowest stock price was C$0.24 and its highest was C$0.91 in the past 12 months.

What is Sona Nanotech Inc’s market cap?

Sona Nanotech Inc’s market cap is C$41.18M.

When is Sona Nanotech Inc’s upcoming earnings report date?

Sona Nanotech Inc’s upcoming earnings report date is Mar 26, 2026 which is in 15 days.

How were Sona Nanotech Inc’s earnings last quarter?

Currently, no data Available

Is Sona Nanotech Inc overvalued?

According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sona Nanotech Inc pay dividends?

Sona Nanotech Inc does not currently pay dividends.

What is Sona Nanotech Inc’s EPS estimate?

Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sona Nanotech Inc have?

Sona Nanotech Inc has 113,005,360 shares outstanding.

What happened to Sona Nanotech Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sona Nanotech Inc?

Currently, no hedge funds are holding shares in TSE:SONA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sona Nanotech Inc

Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.